CXCL12 and breast cancer: Likewise, the migratory activity of MDA-MB-435-Hyg breast cancer cells co-treated with either SDF-1α and Ly294002 or SDF-1α and PD98059 was comparable to the locomotory behaviour of cells treated with the appropriate inhibitor alone (Figure 2C).